51 related articles for article (PubMed ID: 15082748)
1. Psoriatic Arthritis: Pathogenesis and Targeted Therapies.
Azuaga AB; Ramírez J; Cañete JD
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902329
[TBL] [Abstract][Full Text] [Related]
2. The Role of PDE8 in T Cell Recruitment and Function in Inflammation.
Epstein PM; Basole C; Brocke S
Front Cell Dev Biol; 2021; 9():636778. PubMed ID: 33937235
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors.
Betancourt BY; Biehl A; Katz JD; Subedi A
Rheum Dis Clin North Am; 2018 Aug; 44(3):371-391. PubMed ID: 30001781
[TBL] [Abstract][Full Text] [Related]
4. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Spadaccini M; D'Alessio S; Peyrin-Biroulet L; Danese S
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617319
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of apremilast in the treatment of psoriatic arthritis.
Cauli A; Porru G; Piga M; Vacca A; Dessole G; Mathieu A
Immunotargets Ther; 2014; 3():91-6. PubMed ID: 27471702
[TBL] [Abstract][Full Text] [Related]
6. PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.
Mestre L; Redondo M; Carrillo-Salinas FJ; Morales-García JA; Alonso-Gil S; Pérez-Castillo A; Gil C; Martínez A; Guaza C
Br J Pharmacol; 2015 Sep; 172(17):4277-90. PubMed ID: 25994655
[TBL] [Abstract][Full Text] [Related]
7. Promising new treatments for psoriasis.
Dubois Declercq S; Pouliot R
ScientificWorldJournal; 2013; 2013():980419. PubMed ID: 23935446
[TBL] [Abstract][Full Text] [Related]
8. Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445).
El-Elimat T; Figueroa M; Raja HA; Graf TN; Adcock AF; Kroll DJ; Day CS; Wani MC; Pearce CJ; Oberlies NH
J Nat Prod; 2013 Mar; 76(3):382-7. PubMed ID: 23301853
[TBL] [Abstract][Full Text] [Related]
9. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology.
Ernst PB; Garrison JC; Thompson LF
J Immunol; 2010 Aug; 185(4):1993-8. PubMed ID: 20686167
[TBL] [Abstract][Full Text] [Related]
10. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
[TBL] [Abstract][Full Text] [Related]
11. Aspirin attenuates the anti-inflammatory effects of theophylline via inhibition of cAMP production in mice with non-eosinophilic asthma.
Moon HG; Kim YS; Choi JP; Choi DS; Yoon CM; Jeon SG; Gho YS; Kim YK
Exp Mol Med; 2010 Jan; 42(1):47-60. PubMed ID: 19887894
[TBL] [Abstract][Full Text] [Related]
12. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
Banner KH; Press NJ
Br J Pharmacol; 2009 Jul; 157(6):892-906. PubMed ID: 19508401
[TBL] [Abstract][Full Text] [Related]
13. ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
Halpin DM
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):543-61. PubMed ID: 19281073
[TBL] [Abstract][Full Text] [Related]
14. Administration of PDE4 inhibitors suppressed the pannus-like inflammation by inhibition of cytokine production by macrophages and synovial fibroblast proliferation.
Kobayashi K; Suda T; Manabe H; Miki I
Mediators Inflamm; 2007; 2007():58901. PubMed ID: 18274640
[TBL] [Abstract][Full Text] [Related]
15. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
16. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
18. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Moore CS; Earl N; Frenette R; Styhler A; Mancini JA; Nicholson DW; Hebb AL; Owens T; Robertson GS
J Pharmacol Exp Ther; 2006 Oct; 319(1):63-72. PubMed ID: 16809479
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
